Health plan volumes continued to grow faster than the overall business. The base business registered double-digit growth, driven by strong performance across physician and health system lab services. Quest Diagnostics reported better-than-expected first-quarter earnings and revenues. The stock has declined 0.3% compared with 18.3% decline of the industry. In the past year, Quest Diagnostics has outperformed its industry. The stock carries a Zacks Rank #3 (Hold). Over the past several quarters, the overall soft industry trends leading to a low-volume environment have acted as a dampener for Quest Diagnostics. A positive demography and cost reduction initiatives are the other upsides. Quest Diagnostics DGX has been focusing on areas with high potential.
0 kommentar(er)
